Dr. Mookerjee

Bijoyesh P. Mookerjee, MD

Contact Dr. Mookerjee

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer
  2. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial
  3. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
  4. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial
  5. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
  6. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: A randomized Phase II study
  7. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III)
  8. Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
  9. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  10. Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease
  11. Adenovirus DNA polymerase is recognized by human CD8+ T cells
  12. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy
  13. In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy
  14. T Cell Repertoire Complexity Is Conserved after LLME Treatment of Donor Lymphocyte Infusions
  15. Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir
  16. Cytoprotection in acute myelogenous leukemia (AML) therapy
  17. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
  18. Overcoming drug resistance: Targeting more than one site
  19. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy
  20. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB